Alpha-Fetoprotein in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Single Centre Study

#2085

Introduction: Several attempts to determine prognostic factors in neuroendocrine setting have been made, with inconsistent results until now. Alpha-fetoprotein (AFP) has previously been reported as being elevated in some neuroendocrine neoplasms (NENs), even if the actual clinical implications of this marker in this setting are unclear.

Aim(s): Our prospective series was aimed at evaluating the role of AFP as tumor marker in monitoring patients with gastro-entero-pancreatic (GEP)-NENs.

Materials and methods: Between January 2000 and September 2017, all patients with GEP-NENs, were consecutively enrolled and followed-up at our Unit. All the patients were tested for AFP, tumor antigens (CA 125, Ca19.9, CEA, CA 15.3, NSE), Chromogranin A (CgA). Pertinent clinical and histologic data were recorded.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rossi R, Ciafardini C, Conte D, Massironi S,

Keywords: alpha-fetoprotein, neuroendocrine neoplasms, biomarker, prognosis,